These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30694420)

  • 21. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12- and 24-month results.
    Chronopoulos A; Chronopoulos P; Ashurov A; Korb C; Pfeiffer N; Hattenbach LO
    Eur J Ophthalmol; 2022 Jan; 32(1):443-449. PubMed ID: 33601897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema.
    Currie CJ; Holden SE; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):33-43. PubMed ID: 28881150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
    Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
    BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
    Holden SE; Kapik B; Beiderbeck AB; Currie CJ
    Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network.
    Jabbour M; Kodjikian L; Bourdin A; Rougier MB; Serrar Y; Weber M; Massé H; Mazhar D; Perez-Roustit S; Chiquet C; Delyfer MN; Bodaghi B; Touhami S
    J Pers Med; 2024 Feb; 14(3):. PubMed ID: 38540987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluocinolone acetonide intravitreal implant (Retisert
    Leinonen S; Immonen I; Kotaniemi K
    Acta Ophthalmol; 2018 Sep; 96(6):648-651. PubMed ID: 29655222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
    Syed YY
    Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
    ; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
    Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema.
    Bae JH; Lee CS; Lee SC
    Retina; 2011 Jan; 31(1):111-8. PubMed ID: 20856170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
    Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
    Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months.
    Moll-Udina A; Hernanz I; Sainz-de-la-Maza M; Pelegrín L; Coelho-Borges AI; Pazos M; Adán A; Llorenç V
    Int Ophthalmol; 2023 Nov; 43(11):4181-4195. PubMed ID: 37698661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion.
    Cekiç O; Chang S; Tseng JJ; Barile GR; Weissman H; Del Priore LV; Schiff WM; Weiss M; Klancnik JM
    Retina; 2005; 25(7):846-50. PubMed ID: 16205562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.
    Sanford M
    Drugs; 2013 Feb; 73(2):187-93. PubMed ID: 23335133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®).
    Coelho J; Pessoa B; Meireles A
    Ther Adv Ophthalmol; 2019; 11():2515841418820755. PubMed ID: 30643869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
    ; Kempen JH; Altaweel MM; Holbrook JT; Sugar EA; Thorne JE; Jabs DA
    JAMA; 2017 May; 317(19):1993-2005. PubMed ID: 28477440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Evidence of the Long-Term Effectiveness of 0.2 μg/Day Fluocinolone Acetonide Implant in Persistent and Recurrent Diabetic Macular Edema - A Single Center Study.
    Soares RM; Ferreira CC; Fernandes JDS; Madeira C; Silva LMA; Saraiva E; Ribeiro L; Fonseca S
    Clin Ophthalmol; 2024; 18():1057-1066. PubMed ID: 38646183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema.
    Elaraoud I; Attawan A; Quhill F
    Ophthalmol Ther; 2016 Jun; 5(1):95-104. PubMed ID: 26885863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion.
    Ip MS; Gottlieb JL; Kahana A; Scott IU; Altaweel MM; Blodi BA; Gangnon RE; Puliafito CA
    Arch Ophthalmol; 2004 Aug; 122(8):1131-6. PubMed ID: 15302652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained Control from Recurring Non-Infectious Uveitic Macular Edema with 0.19 mg Fluocinolone Acetonide Intravitreal Implant - A Case Report.
    Meira J; Madeira C; Falcão-Reis F; Figueira L
    Ophthalmol Ther; 2019 Dec; 8(4):635-641. PubMed ID: 31506865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.